FDA approves AI-based breast cancer screening software MammoScreen
The FDA has approved MammoScreen®, Therapixel’s explainable and actionable Artificial Intelligence (AI) based software assisting Radiologists in breast cancer screening. This FDA clearance means that MammoScreen will become immediately available to the entire US mammography market. Study findings revealed improvement in readers’ performance in screening for lesions when paired with MammoScreen® compared to radiologists alone.
MammoScreen® automatically detects and characterises suspicious soft tissue lesions and calcifications in mammography and tomosynthesis images, while assessing their likelihood of malignancy. The results are then summarised by the MammoScreen Score™ that characterises suspicion of each lesion scored on a scale of 1-10, with one meaning least likely to reveal malignancy, and ten most likely.
Lees het gehele artikl op: FDA approves AI-based breast cancer screening software MammoScreen® | Pharmafile
